Related Experiment Video
Updated: Jan 14, 2026
Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions
Published on: September 25, 2018
Dual-mode temperature-switchable TSCP probes for precise analysis of PIK3CA mutations and VAF
Xueqiang Wu1, Xuyang Pu2, Nating Xiong3
1Institute of Basic Medical Sciences, Meizhou People's Hospital, Meizhou, 514031, China; Meizhou Clinical Institute of Shantou University Medical College, Shantou University, Meizhou, 514031, China; Guangdong Engineering Technological Research Center of Clinical Molecular Diagnosis and Antibody Drugs, Meizhou Academy of Medical Sciences, Meizhou, 514031, China; Breast Center, Meizhou People's Hospital, Meizhou, 514031, China.
Background:
Precision oncology requires robust methods for simultaneous mutation detection and variant allele frequency (VAF) quantification to guide therapeutic decisions. Current technologies face limitations in sensitivity, cost, and workflow complexity, particularly for assessing tumor heterogeneity. The development of dual-mode temperature-switchable TSCP probes addresses these challenges through an innovative competitive hybridization approach.
Results:
The TSCP platform demonstrates exceptional performance in detecting PIK3CA mutations while precisely quantifying VAF values. By combining temperature-programmed specificity with hybridization chain reaction amplification, the system achieves high sensitivity across a broad dynamic range. Validation studies confirm reliable mutation detection and accurate VAF measurement in both cell line models and clinical samples, outperforming conventional methods in reproducibility and accuracy. The enzyme-free, isothermal workflow operates without specialized instrumentation, offering a practical solution for clinical implementation.
Significance:
This technology represents a significant advancement in molecular diagnostics by integrating mutation detection and clonality assessment in a single assay. Its cost-effective design and modular architecture make it adaptable for various oncogenic mutations, providing clinicians with a powerful tool for therapy selection and tumor heterogeneity monitoring. The platform's capabilities in detecting low-frequency variants suggest promising applications in minimal residual disease monitoring and liquid biopsy analysis, potentially transforming precision oncology practice. Future development will focus on enhancing multiplexing capacity and microfluidic integration to further expand its clinical utility.
